A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Clinical trial NCT06469281 · RECRUITING

Trial details

NCT number: NCT06469281
Sponsor: Regeneron Pharmaceuticals
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Epithelial Ovarian Cancer Primary Peritoneal Carcinoma Fallopian Tube Cancer

Start date: 2024-08-06
Primary completion: 2030-05-27
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.